Market Herald logo

Subscribe

Be the first with the news that moves the market
  • BioVaxys (BIOV) and Procare Health Iberia have finalized a U.S. distribution agreement
  • The agreement covers Papilocare gel and oral Immunocaps and follows the binding term sheet executed in October
  • Procare’s Papilocare prevents and treats HPV-dependent cervical lesions
  • Immunocaps is a nutritional supplement that supports immune function and vaginal microbiota to help re-epithelialization of cervical lesions
  • CEO James Passin spoke with Daniella Atkinson about the agreement
  • Vancouver-based BioVaxys Technology is a clinical-stage biotechnology company developing viral and oncology vaccine platforms, as well as immuno-diagnostics
  • BioVaxys (BIOV) is down by 7.41 per cent, trading at $0.125 per share

BioVaxys (BIOV) and Procare Health Iberia have finalized a U.S. distribution agreement.

Procare Health is a private pharmaceutical company based in Barcelona focused on women’s health. Its products can be found in over 60 countries.

The agreement covers Papilocare gel and oral Immunocaps and follows the binding term sheet executed in October.

Procare’s Papilocare is the world’s first and only patented vaginal gel product supported by clinical evidence to prevent and treat HPV-dependent cervical lesions. It is approved in Europe under a CE mark and is available in 46 countries worldwide.

In several clinical trials, Papilocare showed 50-70 per cent of high-risk HPV clearance after six months.

Immunocaps is an oral over-the-counter (OTC) nutritional supplement that supports immune function and vaginal microbiota to help re-epithelialize cervical lesions.

BioVaxys will immediately begin the regulatory approval process for Papilocare with the U.S. FDA. Marketing and distribution efforts will follow in due course.

As Immunocaps is an OTC supplement, BioVaxys anticipates that regulatory approval will not be required. It plans to begin stocking and distribution in early 2023.

As per the October term sheet, the companies will begin discussions on BioVaxys’ right-of-refusal in the U.S. for Ovosicare and Libicare, Procare’s OTC supplements to support fertility enhancement for late maternity or IVF processes and menopausal symptoms improvements.

According to the World Health Organization, HPV infections can lead to cervical cancer if left untreated.

CEO James Passin spoke with Daniella Atkinson about the agreement.

Vancouver-based BioVaxys Technology is a clinical-stage biotechnology company developing viral and oncology vaccine platforms, as well as immuno-diagnostics.

BioVaxys (BIOV) is down by 7.41 per cent, trading at $0.125 per share as of 12:19 pm ET.


More From The Market Herald
The Market Herald Video

" POET Technologies (TSXV:PTK) partners with LuxshareTech

POET (PTK) has partnered with LuxshareTech, a global technology provider for enterprise and data-communications.
The Market Herald Video

" Trillion Energy (CSE:TCF) discovers an abundance of gas pay at the SASB field

Trillion Energy (TCF) has found new depths to its Guluc 2 well at the SASB gas field.
The Market Herald Video

" Nextech AR Solutions (CSE:NTAR) to spin out Toggle3D

Nextech (NTAR) plans to pursue a direct spin-out of its AI-powered SaaS platform, Toggle3D.

" Defence Therapeutics (CSE:DTC) and CQDM to fund new cancer vaccine platform

Defence Therapeutics (DTC) and CQDM to fund the development of a new cancer vaccine platform.